Jorge Mercado, MD
Pulmonary Disease · Erie, PANPI 1447411970
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Johnson & Johnson at 27.6% of the total. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $101.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- Intuitive Surgical$5K
- Medical Device Business Services, Inc.$4K
- Noah Medical Corporation$3K
- Advanced Respiratory, Inc$2K
- Galvanize Therapeutics, Inc$847
- plus $5K from 24 others
Across 4 payments — averaging $4082.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$16K
What the payments were for
- Consulting fees$7,82329%
- Speaking & faculty fees$1,6406%
- Travel & lodging$2,91511%
- Food & beverage$9,73336%
- Education$4,57917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 42 | $7,377 |
| Intuitive Surgical | 11 | $4,774 |
| Medical Device Business Services, Inc. | 12 | $3,739 |
| Noah Medical Corporation | 15 | $2,807 |
| Advanced Respiratory, Inc | 8 | $1,796 |
| Galvanize Therapeutics, Inc | 14 | $847 |
| Sanofi | 28 | $742 |
| Genentech USA, Inc. | 13 | $511 |
| Pentax Of America, Inc. | 1 | $500 |
| Boehringer Ingelheim | 23 | $457 |
| GSK | 22 | $449 |
| AstraZeneca | 16 | $371 |
| Regeneron Healthcare Solutions, Inc. | 7 | $331 |
| Body Vision Medical Inc. | 2 | $315 |
| Actelion Pharmaceuticals US, Inc. | 3 | $244 |
| Olympus America Inc. | 3 | $168 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| Amgen | 7 | $142 |
| Ambu Inc. | 1 | $125 |
| Verona Pharma, Inc. | 4 | $120 |
| Boston Scientific | 5 | $115 |
| Philips North America LLC | 6 | $115 |
| Baxter Healthcare | 6 | $110 |
| Mylan Specialty L.p. | 4 | $94 |
| Insmed, Inc. | 2 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $67 |
| Electromed, Inc. | 3 | $62 |
| Pfizer | 2 | $31 |
| AbbVie | 1 | $23 |
| Grifols USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$8,858
- Da Vinci Surgical System$4,705
- The Vest System 205 Acute Care$1,640
- Volara System$1,640
- The Monarch Airway Clearance System$1,640
- The MetaNeb System$1,640
- SynclaraCough System$1,640
- MONARCH$1,308
- GALAXY$352
- ALIYA SYSTEM$321
- LungVision$220
- XYWAV$150
- Esbriet$140
- FASENRA$126
- BREZTRI$126
- FARXIGA$126
How this compares
$26,690 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 702 | $542,137 |
| TezspireTezepelumab-Ekko | 109 | $497,598 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 25 | $398,033 |
| Dupixent PenDupilumab | 61 | $224,725 |
| OfevNintedanib Esylate | 12 | $166,688 |
| Breo ElliptaFluticasone/Vilanterol | 325 | $161,072 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $47,418 |
| Spiriva RespimatTiotropium Bromide | 67 | $44,411 |
| Arnuity ElliptaFluticasone Furoate | 155 | $44,367 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $40,665 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $26,751 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 679 | $22,086 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $17,752 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $12,824 |
| EliquisApixaban | 19 | $11,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $449 | $805,9931,295 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $371 | $554,557224 claims |
| Insmed, Inc.Arikayce | $91 | $398,03325 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $457 | $237,850130 claims |
| PfizerEliquis | $31 | $11,56819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Erie
- Stephen KovacsErie$520K
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.